Andere Sprachen Indivior Pharmaceuticals, Inc. London S.E.

Aktien

A42086

US45579U1097

INDV

Pharmazeutika

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:04 24.07.2025			% 5 Tage	Veränd. 1. Jan.
1’238.00 ^GBX	+1.56%		+5.27%	+20.90%

04.05.	Indivior Pharmaceuticals schließt Vereinbarung über beschleunigten Aktienrückkauf im Wert von 175 Millionen Dollar ab	MT
01.05.	Indivior Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 30, 2026

Andere Sprachen

04.05.	Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement
30.04.	Indivior Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30.04.	Indivior Shares Rise After Q1 Adjusted Earnings, Net Revenue Beat Estimates; Lifts 2026 Net Revenue Outlook
30.04.	Indivior Pharmaceuticals : FINAL Indivior Q1 2026 Press Release 2026.04.30
30.04.	Indivior Pharmaceuticals : FINAL Indivior 1Q26 Financial Results Deck Site Version
30.04.	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q1 Revenue $317.0M, vs. FactSet Est of $272.8M
30.04.	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.96 per Share, vs. FactSet Est of $0.66
30.04.	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck April 27
30.04.	Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026
27.04.	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
01.04.	Indivior Pharmaceuticals - New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31.03.	Indivior Pharmaceuticals, Inc. Announces Findings From Cost Impact Model For Monthly Injectable Buprenorphine
23.03.	Top Premarket Gainers
13.03.	Indivior Prices Upsized $450 Million Senior Notes Offering
12.03.	Indivior Pharmaceuticals - New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
12.03.	Indivior Pharmaceuticals Plans $400 Million Private Debt Offering; Shares Down Pre-Bell
12.03.	Indivior announces proposed convertible senior notes offering
26.02.	Indivior's Q4 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance
26.02.	Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026
26.02.	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q4 Revenue $358.0M, vs. FactSet Est of $305.6M
26.02.	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.82 per Share, vs. FactSet Est of $0.67
26.02.	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck
26.02.	Indivior Pharmaceuticals : FINAL Press Release
26.02.	Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck
26.02.	Indivior Pharmaceuticals, Inc. announces an Equity Buyback for $400 million worth of its shares.